

The impact of different recovery approaches on adaptation in physically trained and untrained individuals

Submission date 17/06/2025	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 23/06/2025	Overall study status Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 27/05/2026	Condition category Other	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

This study is looking at how different recovery methods affect the body after physical activity. Researchers want to understand how techniques like cold compression, contrast therapy, blood flow restriction, and others help with muscle recovery, reduce fatigue, and support healing. The goal is to find out which methods work best for improving performance and preventing injuries in active people.

Who can participate?

Adults aged 18 to 45 who are physically active—either amateur or professional athletes—can take part. Participants must be in good health and have no medical issues that would prevent them from exercising.

What does the study involve?

Participants will be randomly placed into one of several groups, each using a different recovery method, or into a control group. Depending on the group, the recovery program will last either 2 weeks, 8 weeks, or 6 months. The study will measure things like muscle strength, inflammation, and how participants feel during recovery. All procedures are safe and supervised.

What are the possible benefits and risks of participating?

Participants may benefit from improved recovery and reduced risk of injury. The risks are very low and may include mild, temporary discomfort from the recovery techniques used.

Where is the study run from?

The study is being carried out at CM Provita in Żory, Poland, with help from local sports clubs and training centers in southern Poland.

When is the study starting and how long is it expected to run for?

January 2025 to October 2026

Who is funding the study?
Investigator initiated and funded

Who is the main contact?
Dr Robert Trybulski, rtrybulski.provita@gmail.com

Contact information

Type(s)

Public, Scientific, Principal investigator

Contact name

Mr Robert Trybulski

ORCID ID

<https://orcid.org/0000-0002-4276-4813>

Contact details

al.Zjednoczonej Europy, 37
Żory
Poland
44-240
+48 502591428
rtrybulski@rehabilitacja-provita.pl

Type(s)

Principal investigator

Contact name

Dr Ireneusz Ryszek

ORCID ID

<https://orcid.org/0000-0002-7365-6014>

Contact details

71 Zięba Street
Tychy
Poland
43-100
-
ryszkielirek@vp.pl

Additional identifiers

Study information

Scientific Title

Assessment of adaptive effects of diversified recovery strategies among individuals with different levels of motor preparation

Acronym

ARM

Study objectives

1. Participants undergoing recovery interventions (Game Ready, IPC, or contrast therapy) will show significantly greater improvements in biomechanical parameters compared to the control group.
2. The effects of recovery strategies will differ depending on the participant's level of motor fitness, with professional athletes demonstrating more pronounced adaptations.
3. Ischemic preconditioning (IPC) will result in higher perfusion and faster recovery than cold compression or contrast therapy.
4. Participants receiving recovery interventions will report lower subjective fatigue and pain compared to the control group.
5. There will be significant differences in the levels of inflammatory and muscle damage biomarkers (e.g., CK, IL-6, CRP) between intervention and control groups over time.
6. Contrast therapy will be more effective in improving tissue elasticity and muscle stiffness compared to cold compression and ischemic preconditioning.
7. Recovery interventions will reduce the risk of performance decline during the training cycle compared to no intervention.

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 11/06/2025, Ethics Committee for Scientific Research of Physiotherapists at the Polish Physiotherapy Association (ul. Zygmunta Modzelewskiego 37/U8, Warszawa, 02-679, Poland; +48 22 840 18 73; biuro@fizjoterapeuci.org), ref: RESOLUTION No. 1/06/2025 of 11 June 2025

Study design

Interventional randomized controlled trial

Primary study design

Interventional

Study type(s)

Efficacy, Prevention, Treatment

Health condition(s) or problem(s) studied

Physical recovery

Interventions

Study Design Description (English Version)

Interventional, randomized controlled trial (RCT) designed to evaluate the adaptive effects of various recovery strategies in individuals with differing levels of motor fitness. The study is prospective and includes both parallel-group and crossover components depending on the intervention duration and subgroup allocation.

Study Type:

Interventional study (clinical trial)

Randomized Controlled Trial (RCT)

Partially crossover in selected phases to minimize inter-subject variability and increase statistical power.

Multicenter setting with standardized protocols implemented across different sports clubs and rehabilitation centers.

Randomization:

Participants are randomly assigned to one of four groups using a computer-generated sequence with block randomization (1:1:1:1). Stratification is applied based on age, gender, and motor preparation level (amateur vs. professional), ensuring balanced distribution across groups.

Study Groups:

GR-C: Cold compression therapy (Game Ready system)

GR-IPC: Ischemic preconditioning (IPC)

GR-KT: Contrast therapy (alternating cold and heat)

GR-K: Control group (no intervention or sham/placebo)

Blinding (Masking):

The study applies single-blind masking, where participants are blinded to the specific nature of the intervention, especially in the case of sham procedures.

Assessors and data analysts are also blinded to group assignments to reduce assessment bias (i.e., assessor-blinded).

Due to the nature of physical interventions, full double-blinding is not feasible, but steps are taken to ensure procedural uniformity and minimize expectancy effects.

Crossover Design:

For selected subgroups and where ethically and logistically feasible, a crossover approach is used. After a washout period, participants may receive a second type of intervention, allowing within-subject comparison and better evaluation of intervention-specific effects.

Summary:

This RCT investigates short-term (2-week), medium-term (8-32 week), and long-term (6-month) outcomes related to recovery strategies. The study incorporates objective physiological, biomechanical, and biochemical measures, as well as subjective recovery and fatigue scales. The design supports high internal validity while reflecting practical implementation in sports and physiotherapy settings

Intervention Type

Mixed

Primary outcome(s)

At baseline, after 2 weeks of intervention, and after 8 weeks. For long-term follow-up groups, we will also conduct measurements at 6 months:

1. Biochemical markers (measured in blood serum):

1.1. Creatine kinase (CK) – measured in U/L; spectrophotometric ELISA; standard laboratory method; Poland, 2023.

- 1.2. C-reactive protein (CRP) – measured in mg/L; immunoturbidimetric assay; Poland, 2023.
- 1.3. Lactate dehydrogenase (LDH) – measured in U/L; spectrophotometric assay; Poland, 2023.
- 1.4. Interleukin-6 (IL-6) – measured in pg/mL; ELISA; Poland, 2023.
- 1.5. Tumor necrosis factor alpha (TNF- α) – measured in pg/mL; ELISA; Poland, 2023.
- 1.6. Cortisol – measured in μ g/dL; immunoassay; Poland, 2023.
- 1.7. Testosterone – measured in ng/dL; immunoassay; Poland, 2023.

2. Mechanical and biomechanical measures:

- 2.1. Muscle tension, stiffness, and elasticity – measured in N/m and milliseconds; assessed using MyotonPRO (Myoton AS), Estonia, 2021.
- 2.2. Reactive Strength Index (RSI) – measured in m/s; assessed with ForceDecks (Vald Performance), Germany, 2020.
- 2.3. Maximal voluntary contraction (MVC) – measured in Newtons (N); assessed using K-Force (Kinvent), Italy, 2023.
- 2.4. Tissue perfusion – measured in Perfusion Units (PU); evaluated using Laser Doppler Flowmeter (Perimed), Sweden, 2004.
- 2.5. Pressure pain threshold (PPT) – measured in kg/cm²; assessed with Algometer FPIX 25 (Medoc), USA, 2021.
- 2.6. Electromyographic activity (EMG) – measured in μ V; recorded using TruScan EMG (Deymed), Germany, 2022.
- 2.7. Range of motion (ROM) – measured in degrees ($^{\circ}$); assessed using Baseline Inclinometer, Italy, 2020.
- 2.8. Body composition (fat percentage, muscle mass) – measured in %; evaluated using AccunIQ BC720, South Korea, 2021.

Key secondary outcome(s)

At baseline, after 2 weeks of intervention, and after 8 weeks. For long-term follow-up groups, we will also conduct measurements at 6 months:

1. Psychometric scales and questionnaires:
 - 1.1. TQR (Total Quality Recovery 0–20 scale)
 - 1.2. Subjective fatigue – assessed using the Borg Rating of Perceived Exertion Scale (6–20 points); international tool.
 - 1.3. Perceived recovery – assessed using the TQR (Total Quality Recovery) Scale (6–20 points); international tool.
 - 1.4. Pain intensity – assessed using the RNS Pain Scale (0–10 points); validated version used in Poland.
2. Maximal voluntary contraction (MVC) – measured in Newtons (N); evaluated using Kinvent K-Force (Kinvent), Italy, 2023.

Completion date

10/10/2026

Eligibility

Key inclusion criteria

1. Age between 18 and 45 years.
2. No contraindications to physical activity – confirmed by a physician.
3. Valid medical clearance for participation in physical training, issued within the past 6 months.
4. Regular physical training history, defined as:
 - 4.1. At least 2 training sessions per week for a minimum of 1 year for amateur participants.
 - 4.2. At least 6 training sessions per week for a minimum of 5 years for professional athletes, as

classified according to the McKay et al. (2022) system.

5. Completed health screening questionnaire with no exclusionary findings.

6. Written informed consent to participate, signed voluntarily after being informed of the study protocol, risks, and benefits.

Participant type(s)

Healthy volunteer, Learner/student, Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Upper age limit

45 years

Sex

All

Total final enrolment

0

Key exclusion criteria

1. Cardiovascular diseases or any medical contraindications to physical exertion.
2. Recent musculoskeletal injuries that limit activity and occurred within 3 months prior to study initiation.
3. History of orthopedic surgery involving the musculoskeletal system within the past 9 months.
4. Active skin diseases or unidentified skin lesions at the intended site of intervention (e.g., for compression devices).
5. Poor general health, excessive fatigue, or symptoms of sports-related depression.
6. Use of substances or medications affecting hemodynamics or masking physiological recovery markers, including:
 - 6.1. Beta-blockers (e.g., metoprolol, bisoprolol)
 - 6.2. Vasodilators (e.g., nitrates, calcium channel blockers)
 - 6.3. Diuretics (e.g., furosemide, hydrochlorothiazide)
 - 6.4. ACE inhibitors and sartans (e.g., enalapril, losartan)
 - 6.5. Anticoagulants (e.g., heparins, NOACs such as apixaban, rivaroxaban)
7. Use of performance-enhancing drugs (doping substances).
8. Refusal to provide informed consent or voluntary withdrawal at any stage of the study.

Date of first enrolment

10/07/2025

Date of final enrolment

20/10/2025

Locations

Countries of recruitment

Poland

Study participating centre

Provita Medical Centre

al.Zjednoczonej Europy, 37

Żory

Poland

44-240

Sponsor information

Organisation

Provita Medical centre

Funder(s)

Funder type

Research council

Funder Name

Investigator initiated and funded

Results and Publications

Individual participant data (IPD) sharing plan

The anonymized datasets will be available upon request from Dr hab. Robert Trybulski (rtrybulski@rehabilitacja-provita.pl), after study completion in October 2026, for 5 years. Access will be granted following formal request and ethical approval. Participant consent for data reuse in anonymized scientific analyses has been obtained.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol file			23/06/2025	No	No